Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19153747 | 0.77 | SRC (0.32) | AHR | |
| SCHEMBL260293 | 0.73 | TNNI3K (0.39) | AHRCMA1 | |
| SCHEMBL18238551 | 0.73 | MEN1 (0.31) | — | |
| SCHEMBL24138418 | 0.69 | GSK3A (0.36) | — | |
| SCHEMBL15964656 | 0.68 | CRBN (0.38) | — | |
| SCHEMBL29545667 | 0.64 | DAO (0.37) | AHRCMA1 | |
| SCHEMBL1531608 | 0.64 | AKT1 (0.37) | — | |
| SCHEMBL659718 | 0.64 | PDE3A (0.37) | AHR | |
| SCHEMBL15386171 | 0.63 | BCL6 (0.40) | AHRCMA1 | |
| SCHEMBL24191776 | 0.62 | GRIA1 (0.36) | AHRCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659300-B2 | Monocyclic anilide spirolactam CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090054408-A1 | Monocyclic anilide spirolactam cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054408-A1 | Monocyclic anilide spirolactam cgrp receptor antagonists | BDKRB1, BDKRB2, CALCRL | AHR 2616/4885CMA1 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.